LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 207 filers reported holding LIGAND PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $513,000 | -47.9% | 6,000 | -4.8% | 0.00% | 0.0% |
| Q4 2021 | $985,000 | +95.4% | 6,305 | +75.1% | 0.00% | 0.0% |
| Q3 2021 | $504,000 | +119.1% | 3,600 | +111.8% | 0.00% | – |
| Q2 2021 | $230,000 | -89.8% | 1,700 | -92.1% | 0.00% | -100.0% |
| Q4 2019 | $2,244,000 | -46.2% | 21,585 | -48.8% | 0.01% | -58.3% |
| Q3 2019 | $4,170,000 | -28.9% | 42,146 | -18.0% | 0.01% | -25.0% |
| Q2 2019 | $5,863,000 | -52.4% | 51,368 | -47.6% | 0.02% | -54.3% |
| Q1 2019 | $12,319,000 | -14.7% | 97,996 | -7.8% | 0.04% | -14.6% |
| Q4 2018 | $14,443,000 | +2411.8% | 106,321 | +2431.5% | 0.04% | +1950.0% |
| Q4 2017 | $575,000 | -15.6% | 4,200 | -16.0% | 0.00% | -33.3% |
| Q3 2017 | $681,000 | -70.2% | 5,000 | -77.0% | 0.00% | -76.9% |
| Q1 2017 | $2,284,000 | -42.7% | 21,700 | -44.5% | 0.01% | -31.6% |
| Q3 2016 | $3,989,000 | +44.7% | 39,100 | +72.2% | 0.02% | +18.8% |
| Q2 2016 | $2,757,000 | – | 22,700 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knott David M Jr | 115,000 | $7,682 | 2.90% |
| VILLERE ST DENIS J & CO LLC | 483,347 | $32,287 | 2.52% |
| Monarch Partners Asset Management LLC | 62,327 | $4,163,444 | 1.23% |
| Chicago Capital, LLC | 319,054 | $21,312,820 | 1.18% |
| RICE HALL JAMES & ASSOCIATES, LLC | 285,634 | $19,080,351 | 1.09% |
| Stephens Investment Management Group LLC | 454,416 | $30,713,977 | 0.56% |
| Smith, Graham & Co., Investment Advisors, LP | 65,372 | $4,366,850 | 0.53% |
| WOODSTOCK CORP | 55,014 | $3,674,935 | 0.49% |
| Court Place Advisors, LLC | 15,533 | $1,037,605 | 0.38% |
| ISTHMUS PARTNERS, LLC | 19,830 | $1,324,644 | 0.20% |